SCHEMBL30987185

SCHEMBL30987185

CC(C)(C)OC(=O)N1C[C@@H](COCc2ccccc2)OCC(O)(Cc2ccccn2)C1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ OPRD1 P41143 1/20 0.38
▸ OPRK1 P41145 1/20 0.38
▸ GPR119 Q8TDV5 3/20 0.37
▸ THRB P10828 2/20 0.37
▸ GRIN2B Q13224 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ TACR1 P25103 2/20 0.36
▸ GAA P10253 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ USP30 Q70CQ3 1/20 0.35
▸ GRM5 P41594 1/20 0.35
▸ GRM1 Q13255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ ACHE P22303 1/20 0.35
▸ RORC P51449 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30987070 0.87 THRB (0.42) GPR119THRBGRIN2BLMNAUSP30
SCHEMBL30987132 0.86 TACR1 (0.40) OPRD1OPRK1GPR119THRBTACR1
SCHEMBL30987111 0.86 RORC (0.41) GPR119THRBTACR1GAASMN1; SMN2
SCHEMBL30987061 0.84 TACR1 (0.38) OPRD1OPRK1GPR119THRBTACR1
SCHEMBL30987128 0.83 TACR1 (0.38) OPRD1OPRK1GPR119THRBTACR1
SCHEMBL30987098 0.83 TACR1 (0.38) GPR119THRBLMNATACR1GAA
SCHEMBL30987095 0.82 RORC (0.42) OPRD1OPRK1GPR119THRBTACR1
SCHEMBL30987059 0.81 RORC (0.41) OPRD1OPRK1GPR119THRBTACR1
SCHEMBL29579004 0.80 TACR1 (0.43) OPRD1OPRK1GPR119THRBTACR1
SCHEMBL28935330 0.80 TACR1 (0.43) GPR119THRBTACR1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479837-B2 Reversible DPP1 inhibitors and uses thereof INSMED INCORPORATED (US) 2025-11-25 — — US disclosed
EP-4646265-A1 NOVEL, REVERSIBLE DPP1 INHIBITORS AND USES THEREOF Insmed Incorporated (US) 2025-11-12 — — EP disclosed
US-20250223284-A1 REVERSIBLE DPP1 INHIBITORS AND USES THEREOF INSMED INCORPORATED 2025-07-10 — — US disclosed
WO-2024148308-A1 NOVEL, REVERSIBLE DPP1 INHIBITORS AND USES THEREOF INSMED INCORPORATED (US) 2024-07-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250223284-A1 REVERSIBLE DPP1 INHIBITORS AND USES THEREOF DPP4, DPP7, DPP9 OPRD1 758/4885OPRK1 1789/4885GPR119 24/4885
US-12479837-B2 Reversible DPP1 inhibitors and uses thereof DPP4, DPP7, DPP9 OPRD1 758/4885OPRK1 1789/4885GPR119 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback